BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1647 related articles for article (PubMed ID: 17854590)

  • 1. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study on the effect of linaclotide in patients with chronic constipation.
    Johnston JM; Kurtz CB; Drossman DA; Lembo AJ; Jeglinski BI; MacDougall JE; Antonelli SM; Currie MG
    Am J Gastroenterol; 2009 Jan; 104(1):125-32. PubMed ID: 19098860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of linaclotide for patients with chronic constipation.
    Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
    Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.
    Bharucha AE; Seide B; Guan Z; Andrews CN; Zinsmeister AR
    Neurogastroenterol Motil; 2008 Jun; 20(6):643-8. PubMed ID: 18312543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans.
    Manabe N; Camilleri M; Rao A; Wong BS; Burton D; Busciglio I; Zinsmeister AR; Haruma K
    Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G970-5. PubMed ID: 20378829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
    Johnston JM; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; O'Dea C; Baird M; Lembo AJ
    Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
    Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
    Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
    Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotrophin-3 improves functional constipation.
    Parkman HP; Rao SS; Reynolds JC; Schiller LR; Wald A; Miner PB; Lembo AJ; Gordon JM; Drossman DA; Waltzman L; Stambler N; Cedarbaum JM;
    Am J Gastroenterol; 2003 Jun; 98(6):1338-47. PubMed ID: 12818279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health.
    Grudell AB; Camilleri M; Jensen KL; Foxx-Orenstein AE; Burton DD; Ryks MD; Baxter KL; Cox DS; Dukes GE; Kelleher DL; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2008 May; 294(5):G1114-9. PubMed ID: 18372395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
    Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
    Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG
    J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.
    Farmer AD; Ruffle JK; Hobson AR
    Neurogastroenterol Motil; 2019 Feb; 31(2):e13492. PubMed ID: 30353623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
    Sweetser S; Camilleri M; Linker Nord SJ; Burton DD; Castenada L; Croop R; Tong G; Dockens R; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1299-306. PubMed ID: 19342506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.
    Wong BS; Camilleri M; McKinzie S; Burton D; Graffner H; Zinsmeister AR
    Am J Gastroenterol; 2011 Dec; 106(12):2154-64. PubMed ID: 21876564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Kim DY; McKinzie S; Kim HJ; Thomforde GM; Burton DD; Low PA; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):111-21. PubMed ID: 15017503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.